SAGITTA contains imatinib mesylate, a second generation tyrosine kinase inhibitor, as hard capsules, is available in the following dosage forms:

-    100mg capsules, packs of 60
-    400mg capsules, packs of 30

SAGITTA is indicated for the treatment of Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL), Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST), unresectable dermatofibrosarcoma protuberans (DFSP), and recurrent and/or metastatic DFSP.


Download Leaflet: